The SMART trial compared two transcatheter aortic valve replacement (TAVR) devices in patients with small aortic annulus, finding better valve performance with a supra-annular self-expanding valve. The trial included 716 low to intermediate risk patients, primarily women, with favorable outcomes at one year, favoring the Evolut PRO/PRO+/FX valve over the SAPIEN 3/3 Ultra. Both valves had similar clinical outcomes, but the self-expanding valve showed superior valve function and hemodynamics. The study’s results provide valuable information for device selection and suggest further follow-up is needed to assess long-term outcomes and durability of the valves.
Source link
SMART trial shows comparable outcomes of two common TAVR devices in small aortic annulus patients
